Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors

Andrew B. Lassman, Khê Hoang-Xuan, Mei Yin C. Polley, Alba A. Brandes, J. Gregory Cairncross, Johan M. Kros, Lynn S. Ashby, Martin J.B. Taphoorn, Luis Souhami, Winand N.M. Dinjens, Nadia N. Laack, Mathilde C.M. Kouwenhoven, Karen L. Fink, Pim J. French, David R. Macdonald, Denis Lacombe, Minhee Won, Thierry Gorlia, Minesh P. Mehta, Martin J. van den Bent

Research output: Contribution to journalArticleAcademicpeer-review

2 Downloads (Pure)

Abstract

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the basis of the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.Anaplastic oligodendroglial tumors (AOTs) are chemotherapy-sensitive brain tumors. We report the final very long-term survival results from European Organization for the Research and Treatment of Cancer 26951 and Radiation Therapy Oncology Group 9402 phase III trials initiated in 1990s, which both studied radiotherapy with/without neo/adjuvant procarbazine, lomustine, and vincristine (PCV) for newly diagnosed anaplastic oligodendroglial tumors. The median follow-up duration in both was 18-19 years. For European Organization for the Research and Treatment of Cancer 26951, median, 14-year, and probable 20-year overall survival rates without versus with PCV were 2.6 years, 13.4%, and 10.1% versus 3.5 years, 25.1%, and 16.8% (N = 368 overall; hazard ratio [HR] 0.78; 95% CI, 0.63 to 0.98; P = .033), with 1p19q codeletion 9.3 years, 26.2%, and 13.6% versus 14.2 years, 51.0%, and 37.1% (n = 80; HR 0.60; 95% CI, 0.35 to 1.03; P = .063), respectively. For Radiation Therapy Oncology Group 9402, analogous results were 4.8 years, 16.5%, and 11.2% versus 4.8 years, 29.1%, and 24.6% (N = 289 overall; HR 0.79; 95% CI, 0.61 to 1.03; P = .08), with codeletion 7.3 years, 25.0%, and 14.9% versus 13.2 years, 46.1%, and 37% (n = 125; HR 0.61; 95% CI, 0.40 to 0.94; P = .02), respectively. With that, the studies show similar long-term survival even without tumor recurrence in a significant proportion of patients after first-line treatment with radiotherapy/PCV.

Original languageEnglish
Pages (from-to)2539-2545
Number of pages7
JournalJournal of clinical oncology : official journal of the American Society of Clinical Oncology
Volume40
Issue number23
DOIs
Publication statusPublished - 10 Aug 2022

Bibliographical note

Research Funding: AbbVie (Inst), Novartis (Inst), Genentech/Roche (Inst),
Aeterna Zentaris (Inst), Kadmon (Inst), BeiGene (Inst), VBI Vaccines (Inst),
Pfizer (Inst), Millennium (Inst), Karyopharm Therapeutics (Inst), Bayer (Inst),
QED Therapeutics (Inst), Orbus Therapeutics (Inst), BMS (Inst), Chimerix (Inst),
NextSource (Inst), DelMar Pharmaceuticals (Inst), Corden (Inst), Kazia
Therapeutics (Inst), Servier (Inst), Semus (Inst), Novocure (Inst

Fingerprint

Dive into the research topics of 'Joint Final Report of EORTC 26951 and RTOG 9402: Phase III Trials With Procarbazine, Lomustine, and Vincristine Chemotherapy for Anaplastic Oligodendroglial Tumors'. Together they form a unique fingerprint.

Cite this